Innoventbio provides an integrated platform for the discovery, development, and GMP‑compliant manufacturing of therapeutic monoclonal antibodies targeting oncology, ophthalmology, and immunology. By leveraging proprietary humanized antibody libraries, high‑throughput screening, and large‑scale bioreactor production, it shortens time‑to‑clinic and reduces reliance on imported biologics, delivering cost‑effective injectable therapies to Chinese hospitals and global partners.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with cancers and autoimmune diseases often lack access to effective biologic therapies due to limited domestic production capacity, high reliance on imported monoclonal antibodies, and lengthy development cycles that delay new treatment options.
Solution
Innoventbio operates an integrated antibody R&D and manufacturing platform that accelerates the discovery, optimization, and large‑scale production of therapeutic monoclonal antibodies for oncology, ophthalmology, and immunology. The company leverages proprietary humanized antibody libraries, high‑throughput screening, and advanced cell‑line development to generate candidates with improved affinity and safety profiles. Once a candidate is validated, Innoventbio employs a GMP‑certified biomanufacturing network to produce bulk drug substance and finished injectable formulations, enabling rapid market entry in China and export to global partners. The end‑to‑end pipeline reduces time‑to‑clinic and lowers cost compared with importing foreign biologics, expanding treatment availability for patients.
Target Audience
Primary customers are Chinese hospitals, oncology and ophthalmology clinics, and pharmaceutical partners seeking domestically produced monoclonal antibody therapeutics.
Features
- Humanized antibody library and phage‑display platforms for rapid target identification
- Integrated preclinical and clinical development workflow with biomarker‑driven trial design
- GMP‑compliant large‑scale cell‑culture bioreactors supporting multiple product lines
- Proprietary formulation technologies for stable injectable monoclonal antibody products
- Robust quality‑control system including multi‑parameter analytics and biosafety testing
- Flexible contract manufacturing services for third‑party biotech partners